Dr. Owen O'Connor, MD

Dr. Owen O'Connor, MD

Medical Oncology  |  
Male  |  
57 y/o

Accepting new patients

Dr. O'Connor is a Professor of Medicine and Experimental Therapeutics, and the Director of the Center for Lymphoid Malignancies, and Co-Program Director of the Lymphoid Development and Malignancy Program in the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center. Over the past two decades, Dr. O'Connor has become an international authority on the management of Hodgkin Lymphoma and non-Hodgkin Lymphoma, as well as the development of novel drugs for the treatment of these diseases. To date, he has pioneered the development of three new drugs approved for the treatment of lymphoma, and collaborated with national and international colleagues on many others. Working in collaboration with the National Cancer Institute (NCI), he was the first to identify the activity of bortezomib (Velcade), a novel class of drugs targeting the proteasome, in patients with relapsed or refractory mantle cell lymphoma, which eventually led to bortezomib becoming the first drug approved by the U.S. Food and Drug Administration for this disease in 2006. He has since developed new treatment regimens integrating bortezomib into the treatment of lymphoma, and conducted the first in human studies of second generation proteasome inhibitors, like carfilzomib. In collaboration with investigators at MSKCC, he conducted the first in human studies of vorinostat, which became the first histone deacetylase inhibitor ever approved for the treatment of cancer in 2005. Vorinostat (Zolinza) was approved in 2005 for the treatment of patients with cutaneous T-cell lymphoma. More recently, he both co-invented and developed pralatrexate (Folytn), which became the first drug ever approved for patients with relapsed or refractory peripheral T-cell lymphoma by the U.S. Food and Drug Administration (FDA) in 2009. Pralatrexate has now been approved for patients in many countries around the world, including Asia. Because of his efforts in developing 2 new drugs approved in T-Cell lymphoma, the Center has developed a unique expertise in treating those rare and complicated diseases, caring for one of the largest populations of T-Cell lymphoma patients in the country. In addition to these drugs, he has recently filed a number of new patents with colleagues at Columbia University on an exciting new class of drugs that target 'master regulators' of cancer cell behavior, which includes NF-kB.& These agents appear active against many cancers including lymphoma, breast cancer and prostate cancer. Presently, Dr. O'Connor is now leading several international studies, many of which are the largest studies ever conducted in various sub-types of lymphoma. His focus is to develop safer drugs that selectively target the unique biology of the cancer cell, all in an effort to minimize the toxic effects of existing chemotherapy treatments. In addition to his efforts in clinical research, Dr. O'Connor runs a laboratory focused on the discovery and development of new drugs for the treatment of lymphoma. His laboratory has developed novel mouse models to accelerate the translation of new discoveries from the laboratory to the clinic. He is widely recognized as an international authority on how to translate novel scientific concepts into patient care.

Columbia Doctors Midtown

51 W 51st St # 200

New York, NY 10019
Get Directions

Accepted insurance

  • Aetna
  • Blue Cross Blue Shield
  • Blue Cross Blue Shield of Louisiana
  • Blue Cross Blue Shield of Massachusetts
  • Capital District Physician's Health Plan (CDPHP)
  • Cigna
  • EmblemHealth
  • Empire Blue Cross Blue Shield
  • Highmark Blue Cross Blue Shield
  • Humana
  • MultiPlan

Learn about Dr. O'Connor

Care Philosophy

We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person. 
...Read More

Dr. O'Connor's Experience

Dr. O'Connor's experience matches your search based on the following criteria:
  • Based on total number of patients treated over the last 12 months
  • Specializes in Medical Oncology
  • Board certified in Medical Oncology
  • No malpractice claims found
  • No sanctions found
  • No board actions found


  • Medical Oncology
  • Hematology
  • Internal Medicine

Board Certifications

  • Medical Oncology
    Accredited by: American Board of Internal Medicine*

Conditions Treated

  • Acute Leukemia
  • All Lymphoma
  • Anal and Rectal Cancer
  • Anemia
  • Autoimmune Diseases
  • Bleeding Disorders
  • Blood Disorders
  • Bone Cancer
  • Bone Disorders
  • Brain Disorders
  • Cancer
  • Central Nervous System Lymphoma
  • Coagulation Disorders (incl. Hemophilia)
  • Colorectal Cancer
  • Deep Vein Thrombosis (DVT)
  • Esophageal Cancer
  • Gastrointestinal Diseases
  • Graft vs Host Disease
  • Hodgkin's Disease
  • Immune Thrombocytopenic Purpura (ITP)
  • Kidney Cancer
  • Leukocytosis
  • Lung Cancer
  • Lymphoma, Large-Cell
  • Lymphosarcoma
  • Macroglobulinemia (incl. Waldenstrom's )
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • Melanoma
  • Mycosis Fungoides
  • Myelodysplastic Syndromes
  • Myeloma
  • Myeloproliferative Disorders
  • Neutropenia
  • Nodular Lymphoma
  • Non-Hodgkin's Lymphoma
  • Pancreatic Cancer
  • Pancytopenia
  • Peripheral T-Cell Lymphoma
  • Prostate Cancer
  • Pulmonary Disease
  • Purpura
  • Secondary Malignancies
  • Skin Cancer
  • Stomach Diseases
  • Urinary Disorders
  • Vascular Disease
  • Venous Embolism and Thrombosis


Read More


  • Bone Marrow Biopsy
  • HPC Transplantation (Stem Cell Transplant)
  • Plasmapheresis
  • Thoracentesis

Background Check

0 Malpractice Claims

No malpractice history found for New York.

0 Sanctions

No sanctions history found for the years that Healthgrades collects data.

0 Board Actions

No board actions found for the years that Healthgrades collects data.


  • New Jersey School Of Medicine
    Medical School | Graduated 1994
  • New York-Presbyterian Hospital-Weill Cornell Medical Center
    Internship Hospital | Completed 1995
  • Memorial Sloan Kettering Cancer Center
    Residency Hospital | Completed 1996
  • New York-Presbyterian Hospital-Weill Cornell Medical Center
    Residency Hospital | Completed 1997
  • Memorial Sloan Kettering Cancer Center
    Fellowship Hospital | Completed 2000
  • New York-Presbyterian Hospital-Weill Cornell Medical Center
    Fellowship Hospital | Completed 2000

Awards & Recognition

Awards & Honors
  • Healthgrades Honor Roll
Media & Publications

Dr. O'Connor has no media or publications listed.

Languages Spoken

  • English

Memberships & Professional Affiliations

Dr. O'Connor does not have any memberships or affiliations listed. If you are Dr. O'Connor and would like to add memberships or affiliations, please update your profile.

Dr. O'Connor's Reviews

Likelihood of recommending Dr. O'Connor to family and friends
based on 20 total reviews (5 with comments)
Dr. O'Connor's Performance
  • Trustworthiness
  • Explains condition(s) well
  • Answers Questions
  • Time well spent
Office & Staff Performance
  • Scheduling
  • Office environment
  • Staff friendliness
  • Average wait time
    Over 45 minutes
Patient Comments (5)
in Manorville ny |
The office staff in office including manager is nasty and does. Not care about the patients concerns or needs they never answer the phone or return the calls
in New York, NY |
While Dr. O'Connor is a very nice man, his staff is not. They seem angry and ready for the end of the day all the time. Terrible bedside manner. Further, there is a serious lack of communication between the doctor and his staff, as you can get 5 different answers from 5 different people. Lastly, we felt lost in the system there and found their follow-up dangerously lacking.
New York, NY |
Dr. O'Connor does not explain things to patients, nor does he take patient comments or complaints seriously. He may be fine with an uncomplicated condition, but if your lymphoma is in any way complicated or rare, he does not have the ability, or willingness, to adapt and modify his preconceived notions of things. In that situation, I would strongly advise to go to an experienced specialist, otherwise you could experience a devastating result as my family suffered.
Top lymphoma specialist. Highly recommend.
in Scarborough, ME |
I would highly recommend this doctor, especially for rare types of cancers. He has a vast knowledge of all types of treatments including many trials he participates in. He participates in research and travels extensively lecturing and teaching. I have PTCL and the local doctors did not know much about it because it is so rare. I am feeling fine and have had several different types of treatments. I have confidence that Dr. O'Connor is treating this in the best way possible and given us hope
Have you seen Dr. Owen O'Connor, MD?
Are you Dr. O'Connor?
Make it easy for patients to share their feedback. Also manage your personalized profile!

Visit Dr. O'Connor

Now Accepting New Patients
Dr. O'Connor accepts 11 insurance carriers
  • Aetna
    Aetna HMO
    Choice Plus POS II
  • Blue Cross Blue Shield
    Blue Card PPO
  • Blue Cross Blue Shield of Louisiana
    BlueConnect HMO
  • Blue Cross Blue Shield of Massachusetts
    Preferred Blue PPO
  • Capital District Physician's Health Plan (CDPHP)
    Capital District Physician's Health Plan (CDPHP) HMO
  • Cigna
    Cigna HMO
    Cigna PPO
  • EmblemHealth
    Health Insurance Plan of Greater New York (HIP) PPO
  • Empire Blue Cross Blue Shield
    Empire Blue Cross Blue Shield HMO
  • Highmark Blue Cross Blue Shield
    Community Blue PPO
  • Humana
    Choice Care PPO
  • MultiPlan
    MultiPlan PPO
    PHCS Network PPO

*Please verify this information when scheduling an appointment.

Hospitals where Dr. O'Connor has admitting privileges

View Hospital Profile

More Oncology Specialists like Dr. O'Connor at Columbia Doctors Midtown

Medical Oncology Specialist
Medical Oncology Specialist
Hematology Specialist